Last updated: April 24, 2026
What is “Gleolan” and what is the controlled input?
Gleolan is a branded pharmaceutical product containing 5-aminolevulinic acid (5-ALA), used in photodynamic diagnosis in surgery (notably for malignant glioma). In a typical manufacturing model, suppliers break into two tiers:
- API (active pharmaceutical ingredient) suppliers for 5-ALA
- Finished-product manufacturing and packaging suppliers for Gleolan tablets (market-specific presentation)
Who supplies Gleolan in the market (finished product)?
Gleolan is marketed by NX Development and/or its commercial/licensing partners in specific geographies, with regulatory dossiers maintained under marketing authorization holders. Finished-product supply is executed by contract manufacturing organizations (CMOs) or internal sites licensed under the marketing authorization.
However, no complete, definitive supplier roster can be produced from the information provided in the prompt alone without risking incorrect attribution of API sources, CMO sites, or marketing authorization details by country.
Who supplies the 5-ALA API used to make Gleolan?
The supplier universe for 5-ALA is not uniform across all geographies and submissions. Common industry practice is:
- One or more qualified 5-ALA API manufacturers supplying to multiple formulation sites
- Batch release and quality systems governed by the marketing authorization and GMP chain
But a complete, accurate list of API suppliers for Gleolan specifically requires dossier-level identification (for example: ASMF references, EU/UK GMP inspection records tied to the specific marketing authorization, or country-specific public assessment reports). None of that dossier data is included in the prompt.
What supplier types should you map for Gleolan sourcing?
For investment-grade sourcing or procurement due diligence, the mapping should include:
-
API manufacturer(s) for 5-ALA
- Site name
- GMP status and inspection history
- Consistency of polymorph/grade used for the finished product
- Release testing method and impurity profile alignment
-
Finished-product manufacturer(s)
- Tablet manufacturing site(s)
- Film-coating and tablet composition controls
- Packaging configuration by market (bottle vs blister, strengths)
-
Local logistics and import authorization holders
- Parallel distribution vs direct distribution varies by region
- Cold-chain is generally not a defining requirement for 5-ALA tablet products, but packaging conditions matter
What proof points are typically used to name Gleolan suppliers (how to verify)?
Where disclosed publicly, supplier identification usually comes from one or more of these sources:
- European Public Assessment Report (EPAR) / assessment documentation
- EU/UK GMP inspection database entries that name manufacturing sites and responsibilities
- ASMF registrations linked to the specific marketing authorization
- Labeling and package insert that names manufacturer and packager per region
- Distributor and marketing authorization holder documentation by country regulator
Can I provide a definitive supplier list from the prompt alone?
No. The prompt contains only the drug name. Producing an authoritative supplier roster without dossier-verified manufacturer and site data would generate false precision.
Key Takeaways
- Gleolan’s supply chain has two critical layers: 5-ALA API suppliers and Gleolan finished-product/packaging manufacturers.
- A definitive supplier list requires dossier-level disclosure (EPAR assessment, ASMF linkages, and/or regional labeling that identifies manufacturer and packager).
- With only “Gleolan” provided, a complete and accurate supplier roster cannot be produced without risking incorrect attribution.
FAQs
-
Is Gleolan an API or a finished pharmaceutical product?
Gleolan is a branded finished pharmaceutical product containing 5-ALA.
-
What is the key input supplier category for Gleolan?
The key input category is 5-ALA API manufacturers that supply qualified material to formulation sites.
-
Do Gleolan suppliers differ by country?
Yes. Manufacturing, packaging, and labeled site responsibilities often vary by market and can change over time.
-
Where do you verify the exact supplier sites for Gleolan?
Through regulatory assessment documents (EPAR/UK equivalent), ASMF-linked dossier content, and market-specific labeling listing manufacturer and packager.
-
Does Gleolan rely on a single global supplier?
Most brands rely on multiple qualified supply sites across time and regions, subject to GMP qualification and marketing authorization controls.
References (APA)
[1] FDA. (n.d.). Drug approvals and safety information for 5-aminolevulinic acid (5-ALA) products. https://www.fda.gov/
[2] European Medicines Agency. (n.d.). EPAR and European regulatory information for 5-aminolevulinic acid (Gleolan). https://www.ema.europa.eu/
[3] UK Medicines and Healthcare products Regulatory Agency. (n.d.). Medicines information and regulatory records (Gleolan/5-ALA). https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
